At the heart of the changing healthcare environment are the payers, private and public, who are increasingly empowered to make decisions affecting which drugs and treatments are prescribed. inVentiv Health’s John Guarino explains that the decision-makers’ heightened focus on value demands an overhaul of traditional marketing and messages.
There is an expectation and early evidence that risk-based monitoring can produce significant improvements in trial quality and productivity. In this paper, inVentiv Health outlines a systematic and rigorous process to assessing risk, using quality risk management principles that will increase the likelihood that your RBM approach will pass regulators’ scrutiny.
Typically, clinical trials conducted in adult populations include patients between the ages of 18 and 65. But changing demographics mean such an age range is no longer broad enough. Medical decisions for those over 65 must be evidence based, which means overcoming the current “age barrier” is clinical trials. inVentiv Health Clinical examines the issue and offers suggestions for sponsors focused on improving research by reflecting changing global demographics.
The importance of adherence is well recognized by industry, government, and a variety of healthcare experts. But motivating adherence is not always well understood. In this paper, inVentiv Health’s PMG shows how behavioral science, combined with online data and scientific evidence, can facilitate the behavior changes that can make a real difference to individual and public health.
The health care industry will be among the most susceptible industries to publicly disclosed and widely scrutinized data breaches. Learn how to protect private data by developing a comprehensive strategy for preventing, preparing and responding to attacks.
This paper addresses how biopharmaceutical companies are turning to strategic outsourcing to address their business needs because these partnerships lower the cost of doing business, while increasing productivity and efficiency.
Learn why FMEA, or Failure Mode and Effects Analysis, should be the standard methodology used in pharmaceutical risk-management and how it can reduce the patient's risk at each step of the medication use process.